(1R,2R)-2-{[4'-({[(3-chlorophenyl)amino]carbonyl}amino)-1,1'-biphenyl-4-yl]carbonyl}cyclopentanecarboxylic acid methyl ester | 959122-14-6

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (1R,2R)-2-{[4'-({[(3-chlorophenyl)amino]carbonyl}amino)-1,1'-biphenyl-4-yl]carbonyl}cyclopentanecarboxylic acid methyl ester
• 英文别名: methyl (1R,2R)-2-{[4'-({[(3-chlorophenyl)amino]carbonyl}amino)-1,1'-biphenyl-4-yl]carbonyl}cyclopentanecarboxylate；methyl (1R,2R)-2-[4-[4-[(3-chlorophenyl)carbamoylamino]phenyl]benzoyl]cyclopentane-1-carboxylate
• CAS: 959122-14-6
• 化学式: C₂₇H₂₅ClN₂O₄
• 分子量: 476.959
• InChiKey: DCMDMFPUVGMPJC-DNQXCXABSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.3
• 重原子数：
  34
• 可旋转键数：
  7
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  84.5
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (1R,2R)-2-{[4'-({[(3-chlorophenyl)amino]carbonyl}amino)-1,1'-biphenyl-4-yl]carbonyl}cyclopentanecarboxylic acid methyl ester 在 lithium hydroxide 作用下， 以 四氢呋喃 、 水 为溶剂， 生成 (1R,2R)-2-{[4'-({[(3-chlorophenyl)amino]carbonyl}amino)-1,1'-biphenyl-4-yl]carbonyl}cyclopentanecarboxylic acid
  参考文献：
  名称：

  Validation of Diacyl Glycerolacyltransferase I as a Novel Target for the Treatment of Obesity and Dyslipidemia Using a Potent and Selective Small Molecule Inhibitor

  摘要：

  A highly potent and selective DGAT-1 inhibitor was identified and used in rodent models of obesity and postprandial chylomicron excursion to validate DGAT-1 inhibition as a novel approach for the treatment of metabolic diseases. Specifically, compound 4a conferred weight loss and a reduction in liver triglycerides when dosed chronically in DIO mice and depleted serum triglycerides following a lipid challenge in a dose-dependent manner, thus, reproducing major phenotypical characteristics of DGAT-1(-/-) mice.

  DOI：

  10.1021/jm7013887
• 作为产物：
  描述：

  (1R,2R)-2-[(4-氨基-1,1-联苯-4-基)羰基]环戊烷羧酸甲酯 、 间氯苯异氰酸酯 以 四氢呋喃 为溶剂， 生成 (1R,2R)-2-{[4'-({[(3-chlorophenyl)amino]carbonyl}amino)-1,1'-biphenyl-4-yl]carbonyl}cyclopentanecarboxylic acid methyl ester
  参考文献：
  名称：

  Validation of Diacyl Glycerolacyltransferase I as a Novel Target for the Treatment of Obesity and Dyslipidemia Using a Potent and Selective Small Molecule Inhibitor

  摘要：

  A highly potent and selective DGAT-1 inhibitor was identified and used in rodent models of obesity and postprandial chylomicron excursion to validate DGAT-1 inhibition as a novel approach for the treatment of metabolic diseases. Specifically, compound 4a conferred weight loss and a reduction in liver triglycerides when dosed chronically in DIO mice and depleted serum triglycerides following a lipid challenge in a dose-dependent manner, thus, reproducing major phenotypical characteristics of DGAT-1(-/-) mice.

  DOI：

  10.1021/jm7013887

文献信息

• WO2007/137107
  申请人：——

  公开号：——

  公开（公告）日：——
• Validation of Diacyl Glycerolacyltransferase I as a Novel Target for the Treatment of Obesity and Dyslipidemia Using a Potent and Selective Small Molecule Inhibitor
  作者：Gang Zhao、Andrew J. Souers、Martin Voorbach、H. Doug Falls、Brian Droz、Sevan Brodjian、Yau Yi Lau、Rajesh R. Iyengar、Ju Gao、Andrew S. Judd、Seble H. Wagaw、Matthew M. Ravn、Kenneth M. Engstrom、John K. Lynch、Mathew M. Mulhern、Jennifer Freeman、Brian D. Dayton、Xiaojun Wang、Nelson Grihalde、Dennis Fry、David W. A. Beno、Kennan C. Marsh、Zhi Su、Gilbert J. Diaz、Christine A. Collins、Hing Sham、Regina M. Reilly、Michael E. Brune、Philip R. Kym

  DOI：10.1021/jm7013887

  日期：2008.2.1

  A highly potent and selective DGAT-1 inhibitor was identified and used in rodent models of obesity and postprandial chylomicron excursion to validate DGAT-1 inhibition as a novel approach for the treatment of metabolic diseases. Specifically, compound 4a conferred weight loss and a reduction in liver triglycerides when dosed chronically in DIO mice and depleted serum triglycerides following a lipid challenge in a dose-dependent manner, thus, reproducing major phenotypical characteristics of DGAT-1(-/-) mice.